Blood transfusions at home
A Pilot Study of Home Blood Transfusions for Patient With Cancer Who Have Transfusion Dependent Cytopenias
This pilot tests whether giving required blood transfusions at home works well and is acceptable for adults with transfusion-dependent blood cancers or bone marrow failure who receive care at SKCCC.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT07121140 on ClinicalTrials.gov |
What this trial studies
This is a single-arm pilot at Thomas Jefferson University Hospital offering home blood draws and same-day transfusions for adults with hematologic malignancies or marrow failure who are transfusion dependent. Participants receive 1-2 blood products per week for up to five weeks (total of up to 5 transfusions), with staff documenting barriers to delivering transfusions in the home. Data are collected through surveys at each visit, end-of-intervention participant surveys, and semi-structured qualitative interviews. The protocol excludes patients with prior transfusion reactions, significant heart failure, or unstable housing, and limits enrollment to those living within 30 miles of the Center City SKCCC location.
Who should consider this trial
Good fit: Adults (18+) with transfusion-dependent cytopenias from hematologic malignancy or bone marrow failure who receive care at SKCCC, have no history of transfusion reactions, speak English or Spanish, are willing to allow staff into their home, and live within about 30 miles of the Center City SKCCC.
Not a fit: Patients with a history of transfusion reactions, significant heart failure (AHA stage C or NYHA II-IV), unstable housing or incarceration, poor venous access, or who live outside the 30-mile catchment are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, eligible patients could receive needed transfusions at home, reducing travel and clinic visits and improving convenience and comfort.
How similar studies have performed: Home transfusion programs have been piloted in other health systems with promising feasibility and patient satisfaction, but randomized or large-scale outcome data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study: * Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study * Male or female, over the age of 18 * Must meet definition of transfusion dependence (require at least 2 blood product transfusions over a 28-day period) * Receive their cancer care at SKCCC * Have a history of blood product transfusions and NO history of transfusion reactions, * Live within a 30-mile range of the Center City SKCCC location. * Must be willing to allow people into the home Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this study: * Patients who have a history of a transfusion reaction * Heart failure as defined by AHA stage C or NYHA Class II-IV * Non-English or Spanish speaking * Are unhoused * Are incarcerated * Have poor venous access * Diagnosis of Solid Tumor malignancy * Women who are pregnant
Where this trial is running
Philadelphia, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Adam Binder, MD — Adam.Binder@jefferson.edu
- Study coordinator: Adam Binder, MD
- Email: Adam.Binder@jefferson.edu
- Phone: 215-955-8874
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.